首页> 外文期刊>Cardiology >Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integr
【24h】

Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integr

机译:非ST段抬高的急性冠状动脉综合征和多支冠状动脉疾病患者的特征,治疗和预后:来自PURSUIT的观察(不稳定型心绞痛的血小板糖蛋白IIb / IIIa:使用整数抑制受体

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The 6-month clinical outcome of patients with multivessel disease enrolled in PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy) is described. Patients with complete angiography data were included; multivessel disease was stratified according to the treatment strategy applied early during hospitalization, i.e. medical treatment, percutaneous coronary intervention (PCI) (balloon), PCI (stent), or coronary artery bypass grafting (CABG). METHODS: Patients were divided into three groups according to the treatment strategy applied during the first 30 days of enrolment. Patients who did not undergo a percutaneous or surgical coronary intervention were classified as medically treated. Patients who underwent a PCI (prior to a possible CABG) were separated from those who underwent a CABG (prior to a possible PCI). The PCI group was further subdivided: patients receiving >/=1 coronary stents were separated from those in whom no stents were used.RESULTS: The mortality rate at 30 days was 6.7, 3.9, 2.4 and 4.8% for the medical treatment, PCI (balloon), PCI (stent) and CABG groups, respectively (p value = 0.002). Differences as observed at 30 days were still present at 6-month follow-up with 11.1, 5.8, 5.5 and 6.5% mortality event rates for the aforementioned groups (p value = 0.002). The 30-day myocardial infarction (MI) rate according to the opinion of the Clinical Events Committee was lower among medically than non-medically treated patients, with the highest event rate observed in the CABG group (27.7%). Approximately half of the MIs in the PCI and CABG subgroups occurred within 48 h after the procedure. CONCLUSIONS: The observed differences in clinical outcomes are explained by an imbalance in baseline characteristics and comorbid conditions between the analyzed groups of patients.
机译:背景:描述了参加PURSUIT(不稳定型心绞痛的血小板糖蛋白IIb / IIIa:使用整联蛋白疗法抑制受体)的多支血管疾病患者的6个月临床结局。包括具有完整血管造影数据的患者;根据住院期间早期应用的治疗策略对多支血管疾病进行分层,即药物治疗,经皮冠状动脉介入治疗(PCI)(气球),PCI(支架)或冠状动脉搭桥术(CABG)。方法:根据入组前30天的治疗策略将患者分为三组。未经历经皮或外科冠状动脉介入治疗的患者被分类为药物治疗。接受过PCI(在可能的CABG之前)的患者与接受过CABG(在可能的PCI之前)的患者是分开的。 PCI组进一步细分:接受> / = 1冠状动脉支架的患者与未使用支架的患者分开。结果:药物治疗30天的死亡率分别为6.7%,3.9%,2.4%和4.8%。气球,PCI(支架)和CABG组(p值= 0.002)。对于上述各组,在6个月的随访中,仍存在30天观察到的差异,死亡率分别为11.1、5.8、5.5和6.5%(p值= 0.002)。根据临床事件委员会的意见,在药物治疗的患者中,30天的心肌梗塞(MI)发生率低于未药物治疗的患者,在CABG组中观察到的事件发生率最高(27.7%)。 PCI和CABG亚组中大约一半的MI发生在手术后48小时内。结论:观察到的临床结果差异可以通过分析的患者组之间基线特征和合并症的不平衡来解释。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号